NORD®Corporate Council Members, 2008-2009
NORD is grateful to the following companies who are active members of
the Corporate Council
Accredo Health, Inc.
Acorda Therapeutics
Actelion Pharmaceuticals US, Inc.
Alexion Pharmaceuticals, Inc.
Allergan
Altus Pharmaceuticals
Amicus Therapeutics, Inc.
Antigenics, Inc.
Applied Genetic Technologies Corp.
Aspreva Pharmaceuticals
Astra Zeneca Pharmaceuticals LP
Aton Pharma Inc
Avigen, Inc.
Bausch & Lomb Pharmaceuticals
Baxter BioScience
BioMarin Pharmaceuticals, Inc.
Celgene Corporation
Centric Health Resources
CSL Behring
Duchesnay, Inc.
Endo Pharmaceuticals
Engage Health, Inc.
Enobia, Inc.
Errant Gene Therapeutics
FFF Enterprises
FoldRX Pharmaceuticals, Inc.
Genzyme Corporation
Hemophelia Health Services
HPS Group LLC
Hyperion Therapeutics
IDIS Pharmaceuticals
Impax Laboratories, Inc.
IKARIA
Insmed Incorporated
Jazz Pharmaceuticals
Johnson & Johnson
Lundbeck, Inc.
Mark Krueger & Associates, Inc.
Medtronic, Inc.
Millennium Pharmaceuticals
Novartis
NPS Pharmaceuticals, Inc.
Pfizer, Inc.
Neurochem, Inc.
NexGenix Pharmaceuticals
Prestwick Pharmaceuticals
PTC Therapeutics Inc
Purdue Pharma
Questcor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc.
Rare Disease Therapeutics, Inc.
Sanofi-Aventis, Inc.
Shire Pharmaceuticals
Sigma-Tau Pharmaceuticals
Soligenix, Inc.
Synageva BioPharma, Inc.
Ucyclyd Pharma (Medicis)
United Therapeutics Corporation
ViroPharma, Inc.
ZioPharm Oncology, Inc.
For information on the NORD Corporate Council please
contact:
Michael S. Langan, Vice President of Industry Relations
National Organization for Rare Disorders (NORD)
2338 Channing Way, Suite 6
Berkeley, CA 94704
email - mlangan@rarediseases.org
back to Corporate Council Homepage